Haemonetics Corp. (NYSE:HAE) shares, rose in value, with the stock price up by 3.80% to the previous day’s close as strong demand from buyers drove the stock to $90.99.
Actively observing the price movement in the last trading, the stock closed the session at $87.66. The PE ratio was 36.91 over 12-month period. Referring to stock’s 52-week performance, its high was $95.26, and the low was $70.74. On the whole, HAE has fluctuated by 8.21% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 1.29B, with a low estimate of 326.85M and a high estimate of 332.05M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 329.11M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that HAE’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 3.08, with the price of HAE currently trading nearly 7.09% and 14.12% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 70.39, while the 7-day volatility ratio is showing 3.61% which for the 30-day chart, stands at 2.42%. Furthermore, Haemonetics Corp. (HAE)’s beta value is 0.35, and its average true range (ATR) is 2.29.
A comparison of Haemonetics Corp. (HAE) with its peers suggests the former has fared considerably weaker in the market. HAE showed an intraday change of 3.80% in last session, and over the past year, it grew by 10.52%%.
Data on historical trading for Haemonetics Corp. (NYSE:HAE) indicates that the trading volumes over the past 3 months, they’ve averaged 483.95K. According to company’s latest data on outstanding shares, there are 50.45 million shares outstanding.
Nearly 0.98% of Haemonetics Corp.’s shares belong to company insiders and institutional investors own 100.84% of the company’s shares. The stock has risen by 6.41% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the HAE stock heading into the next quarter.
